한글목차

아토피 피부염의 동향과 전망

세계 아토피 피부염 시장은 2024년부터 2030년까지 9.4%의 연평균 복합 성장률(CAGR)로 2030년까지 약 233억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 빠른 기술 발전과 자금 조달 증가, 그리고 연구개발에 대한 정부 지원 증가입니다. 세계 아토피 피부염 시장의 미래는 병원 약국, 소매 약국, 온라인 약국 시장에서의 기회로 인해 유망합니다.

부문별 아토피 피부염

아토피 피부염 세계 시장에 대해 약제 유형별, 투여 방법별, 유통 채널별, 지역별 예측을 제공합니다.

아토피 피부염 시장 인사이트

Lucintel의 예측에 따르면, 아토피 피부염에 대한 치료법에 대한 인식이 높아짐에 따라 예측 기간 동안 생물학적 제제가 가장 높은 성장률을 보일 것으로 예상됩니다.

아토피 피부염의 유병률이 높기 때문에 병원 약국이 이 시장에서 가장 큰 부문을 차지할 것으로 보입니다.

북미는 환자들의 치료에 대한 인식이 높아지고 있고, 이 지역에 많은 자체 제조업체가 존재하기 때문에 예측 기간 동안 가장 규모가 큰 지역으로 남을 것으로 보입니다.

자주 묻는 질문

Q1. 시장 규모 :

A1. 세계 아토피 피부염 시장은 2030년까지 약 233억 달러에 달할 것으로 예상됩니다.

Q2. 시장 성장 예측은 다음과 같습니다.

A2. 아토피 피부염 세계 시장은 2024년부터 2030년까지 연평균 9.4%의 성장률을 보일 것으로 예상됩니다.

Q3. 시장 성장에 영향을 미치는 주요 촉진요인은 다음과 같습니다.

A3.이 시장의 주요 촉진요인은 빠른 기술 발전과 자금 조달 증가이며, 연구 개발에 대한 정부 지원도 증가하고 있습니다.

Q4. 시장의 주요 부문은 다음과 같습니다.

A4. 아토피 피부염 시장의 미래는 병원 약국, 소매 약국, 온라인 약국 시장에서의 기회로 인해 유망합니다.

Q5. 시장 주요 기업은 다음과 같습니다.

A5. 아토피 피부염 주요 기업은 다음과 같습니다.

• Bayer
• AbbVie
• Incyte
• Novartis International
• Arcutis Biotherapeutics
• Bristol-Myers Squibb
• Regeneron Pharmaceuticals

Q6. 향후 가장 큰 시장 부문은 다음과 같습니다.

A6. Lucintel의 예측에 따르면, 아토피 피부염 치료법에 대한 인식이 높아짐에 따라 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상되는 것은 생물학적 제제입니다.

Q7. 시장에서 향후 5년간 가장 큰 시장이 될 것으로 예상되는 지역은 어디입니까?

A7. 북미는 환자들의 치료에 대한 인식이 높아지고 있고, 이 지역에 많은 자체 제조업체가 존재하기 때문에 예측 기간 동안에도 가장 규모가 큰 지역입니다.

Q8. 보고서 사용자 정의가 가능합니까?

A8. 네. Lucintel은 추가 비용없이 10%의 사용자 정의를 제공합니다.

목차

제1장 주요 요약

제2장 세계의 아토피 피부염 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 아토피 피부염 시장 동향(2018-2023년)과 예측(2024-2030년)
• 약제 클래스별 아토피 피부염 세계 시장
  • PDE-4 억제제
  • 코르티코스테로이드
  • 생물학적 제제
  • 칼시뉴린 억제제
  • 기타
• 투여 방법별 아토피 피부염 세계 시장
  • 국소
  • 주사
  • 경구
• 유통 채널별 아토피 피부염 세계 시장
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제4장 지역별 시장 동향과 예측 분석(2018-2023년)

• 지역별 아토피 피부염 세계 시장
• 북미의 아토피 피부염 시장
• 유럽의 아토피 피부염 시장
• 아시아태평양의 아토피 피부염 시장
• 기타 지역의 아토피 피부염 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
• 세계의 아토피 피부염 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 아토피 피부염 시장 능력 확대
  • 세계의 아토피 피부염 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증과 라이선싱

제7장 주요 기업 개요

• Bayer
• AbbVie
• Incyte
• Novartis International
• Arcutis Biotherapeutics
• Bristol-Myers Squibb
• Regeneron Pharmaceuticals

영문목차

Atopic Dermatitis Trends and Forecast

The future of the global atopic dermatitis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global atopic dermatitis market is expected to reach an estimated $23.3 billion by 2030 with a CAGR of 9.4% from 2024 to 2030. The major drivers for this market are swift technological advancement and increase in funding, coupled with a rise in government support for research and development.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Atopic Dermatitis by Segment

The study includes a forecast for the global atopic dermatitis by drug class, mode of administration, distribution channel, and region.

Atopic Dermatitis Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

• PDE-4 Inhibitor
• Corticosteroids
• Biologics
• Calcineurin Inhibitors
• Others

Atopic Dermatitis Market by Mode of Administration [Shipment Analysis by Value from 2018 to 2030]:

• Topical
• Injectable
• Oral

Atopic Dermatitis Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Atopic Dermatitis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Atopic Dermatitis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies atopic dermatitis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the atopic dermatitis companies profiled in this report include-

• Bayer
• AbbVie
• Incyte
• Novartis International
• Arcutis Biotherapeutics
• Bristol-Myers Squibb
• Regeneron Pharmaceuticals

Atopic Dermatitis Market Insights

Lucintel forecasts that biologic is expected to witness the highest growth over the forecast period due to rise in awareness regarding the availability of treatments for the disease.

Within this market, hospital pharmacy will remain the largest segment due to notable prevalence of atopic dermatitis.

North America will remain the largest region over the forecast period due to growing treatment awareness among the patient population and existence of substantial in-house manufacturers in the region.

Features of the Global Atopic Dermatitis Market

Market Size Estimates: Atopic dermatitis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Atopic dermatitis market size by drug class, mode of administration, distribution channel, and region in terms of value ($B).

Regional Analysis: Atopic dermatitis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, mode of administration, distribution channels, and regions for the atopic dermatitis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the atopic dermatitis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the atopic dermatitis market size?

Answer: The global atopic dermatitis market is expected to reach an estimated $23.3 billion by 2030.

Q2. What is the growth forecast for atopic dermatitis market?

Answer: The global atopic dermatitis market is expected to grow with a CAGR of 9.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the atopic dermatitis market?

Answer: The major drivers for this market are swift technological advancement and increase in funding, coupled with a rise in government support for research and development.

Q4. What are the major segments for atopic dermatitis market?

Answer: The future of the atopic dermatitis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.

Q5. Who are the key atopic dermatitis market companies?

Answer: Some of the key atopic dermatitis companies are as follows:

• Bayer
• AbbVie
• Incyte
• Novartis International
• Arcutis Biotherapeutics
• Bristol-Myers Squibb
• Regeneron Pharmaceuticals

Q6. Which atopic dermatitis market segment will be the largest in future?

Answer: Lucintel forecasts that biologic is expected to witness the highest growth over the forecast period due to rise in awareness regarding the availability of treatments for the disease.

Q7. In atopic dermatitis market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing treatment awareness among the patient population and existence of substantial in-house manufacturers in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the atopic dermatitis market by drug class (PDE-4 inhibitor, corticosteroids, biologics, calcineurin inhibitors, and others), mode of administration (topical, injectable, and oral), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Atopic Dermatitis Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Atopic Dermatitis Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Atopic Dermatitis Market by Drug Class
  • 3.3.1: PDE-4 Inhibitor
  • 3.3.2: Corticosteroids
  • 3.3.3: Biologics
  • 3.3.4: Calcineurin Inhibitors
  • 3.3.5: Others
• 3.4: Global Atopic Dermatitis Market by Mode of Administration
  • 3.4.1: Topical
  • 3.4.2: Injectable
  • 3.4.3: Oral
• 3.5: Global Atopic Dermatitis Market by Distribution Channel
  • 3.5.1: Hospital Pharmacies
  • 3.5.2: Retail Pharmacies
  • 3.5.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Atopic Dermatitis Market by Region
• 4.2: North American Atopic Dermatitis Market
  • 4.2.1: North American Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
  • 4.2.2: North American Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.3: European Atopic Dermatitis Market
  • 4.3.1: European Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
  • 4.3.2: European Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.4: APAC Atopic Dermatitis Market
  • 4.4.1: APAC Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
  • 4.4.2: APAC Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.5: ROW Atopic Dermatitis Market
  • 4.5.1: ROW Atopic Dermatitis Market by Drug Class: PDE-4 Inhibitor, Corticosteroids, Biologics, Calcineurin Inhibitors, and Others
  • 4.5.2: ROW Atopic Dermatitis Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Atopic Dermatitis Market by Drug Class
  • 6.1.2: Growth Opportunities for the Global Atopic Dermatitis Market by Mode of Administration
  • 6.1.3: Growth Opportunities for the Global Atopic Dermatitis Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Atopic Dermatitis Market by Region
• 6.2: Emerging Trends in the Global Atopic Dermatitis Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Atopic Dermatitis Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Atopic Dermatitis Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Bayer
• 7.2: AbbVie
• 7.3: Incyte
• 7.4: Novartis International
• 7.5: Arcutis Biotherapeutics
• 7.6: Bristol-Myers Squibb
• 7.7: Regeneron Pharmaceuticals